Literature DB >> 8039756

Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature.

C Schiavotto1, M Ruggeri, F Rodeghiero.   

Abstract

BACKGROUND: High dose intravenous immunoglobulin (h.d. Ig) is increasingly used in several hematological diseases. There are few data on the safety and no review of side effects after this treatment is available. We review here the literature on reported adverse reactions after h.d. Ig and report our own experience in the management of 83 patients with idiopathic thrombocytopenic purpura (ITP). PATIENTS AND METHODS: Computer assisted (Medline) and manual searches of the cumulative Index Medicus were undertaken to retrieve articles reporting side effects after infusion of h.d. Ig, published between 1981 and August 1993. Our own experience is based on clinical records of 83 patients, 56 females, 27 male, with a median age of 61 years (range 8-84), treated with h.d. Ig for acute or chronic ITP between 1985 and June 1993. RESULTS AND DISCUSSION: Major adverse reactions included aseptic meningitis (14 cases), hemolytic anemia (8 cases) and renal dysfunction (12 cases). The most frequently reported mild side effect was headache. We have had 2 cases of severe skin reactions, 1 case of acute renal failure, 3 cases of severe headache and 1 case of chills and fever. For other 3 cases, an anaphylactic/oid reaction, caused by a too rapid infusion rate, occurred. Thus, 10/83 (12%) patients, 7 female and 3 male, developed side effects, but they were unpredictable and severe in only 3 cases (4%). Side effects developed only in 21/480 (4%) infusions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8039756

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  11 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

2.  A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.

Authors:  Melvin Berger
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

Review 3.  [Adult autoimmune thrombocytopenia: diagnosis and treatment].

Authors:  Klaus Lechner; Ansgar Weltermann; Ingrid Pabinger
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

4.  Facial vasculitic rash associated with intravenous immunoglobulin.

Authors:  M Howse; L Bindoff; A Carmichael
Journal:  BMJ       Date:  1998-11-07

Review 5.  Drug-induced aseptic meningitis: diagnosis and management.

Authors:  S Jolles; W A Sewell; C Leighton
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

6.  A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.

Authors:  Thomas S Lin; Wendy Stock; Huiping Xu; Mitch A Phelps; Margaret S Lucas; Sara K Guster; Bruce R Briggs; Carolyn Cheney; Pierluigi Porcu; Ian W Flinn; Michael R Grever; James T Dalton; John C Byrd
Journal:  Leuk Lymphoma       Date:  2009-12

7.  A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy.

Authors:  Yu Ji Lee; Jae Uk Shin; Jeeyun Lee; Kihyun Kim; Won Seog Kim; Jin Seok Ahn; Chul Won Jung; Won Ki Kang
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153

Review 8.  Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.

Authors:  Peter D Han; Russell D Cohen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.

Authors:  Roberto Stasi; Magaral Murali; Marc Michel; Jean-François Viallard; Aristoteles Giagounidis; Ann Janssens; Jason Legg; Robert Deuson; Mark D Danese
Journal:  Int J Hematol       Date:  2012-05-05       Impact factor: 2.490

10.  Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.

Authors:  Fatih Tufan; Sevil Kamali; Burak Erer; Ahmet Gul; Murat Inanc; Lale Ocal; Meral Konice; Orhan Aral
Journal:  Clin Rheumatol       Date:  2007-07-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.